• Innovative Company SHIONOGI

What's New

  • Show All
2017/12/05
Participation in PSCI (Pharmaceutical Supply Chain Initiative)
2017/11/27
Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares
2017/11/07
Audio webcasting: First Half of FY2017 Financial Results
2017/10/31
Notice of signing a capital investment and business alliance agreement
2017/10/30
Financial Results for the Second Quarter of FY2017
2017/10/25
Regarding the Filing for Approval of S-033188 in Japan Shionogi filed for approval to manufacture and sell S-033188 for the treatment of Influenza Types A and B under the priority review system of the Ministry of Health, Labor, and Welfare of Japan (“Sakigake fast-track review”)
2017/10/23
Confirmatory Results of the Second Phase 3 Lusutrombopag (S-888711) Study (L-PLUS 2) Presented at the 2017 Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD)
2017/10/23
Notice of Revisions to Earnings Forecasts
2017/10/13
Shionogi Inc. and Purdue Pharma L.P. Announce U.S. Availability of Symproic® (naldemedine) for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
2017/10/13
The dispute with the Boards of Appeal of the European Patent Office between Merck & Co., Inc. regarding HIV integrase inhibitor
2017/10/12
Shionogi Received “2017 Award for Excellence in Corporate Disclosure” From the Securities Analysts Association of Japan (SAAJ)
2017/10/06
SHIONOGI TO PRESENT S-033188 PHASE 3 CAPSTONE-1 STUDY RESULTS FOR TREATMENT OF INFLUENZA AT IDWEEK 2017
2017/10/05
SHIONOGI PRESENTS POSITIVE CLINICAL EFFICACY TRIAL RESULTS AND IN VITRO DATA ON CEFIDEROCOL, AT IDWEEK 2017